Who produces the targeted drug Sorafenib?

As a molecularly targeted chemotherapy drug approved by the U.S. Food and Drug Administration(FDA), Sorafenib can inhibit angiogenesis and tumor cell proliferation, thereby improving the overall survival rate of patients with hepatocellular carcinoma (HCC). Additionally, sorafenib is an oral multikinase inhibitor that is available as monotherapy for renal cell carcinoma. However, poor water solubility, low bioavailability, unfavorable pharmacokinetic properties and adverse side effects (anorexia, gastrointestinal bleeding, severe skin toxicity, etc.) severely limit its clinical application.

Due to the presence of the amide and pyridine moieties, pH dependence Sorafenib is more soluble in acidic environments. Sorafenib tosylate is produced by Bayer Pharmaceuticals in Leverkusen, Germany. The water solubility of sorafenib has been improved (65ng/mL), but its solubility in water is still poor. Sorafenibhas been approved for kidney cancer, hepatocellular carcinoma and differentiated thyroid cancer. The recommended oral dose is 400 mg, equivalent to two tablets per day (200 mg/tablet).

The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.